Sort
48,018 grants matching “immunotherapy”
Predicting Relapse at the Time of Diagnosis in Acute Lymphoblastic Leukemia
$604,026Kara Lynn Davis · Stanford University · R01 · FY2022 · CA
T CELL VACCINE--A CLINICAL TRIAL FOR PROGRESSIVE MS
$604,010University Of Southern California · R01 · FY2001 · NS
Novel Transgenic Mouse Models Addressing Outstanding Translational Barriers in Antibody-Based Therapeutics
$603,948Stylianos Bournazos · Rockefeller University · R01 · FY2023 · CA
Novel Transgenic Mouse Models Addressing Outstanding Translational Barriers in Antibody-Based Therapeutics
$603,948Stylianos Bournazos · Rockefeller University · R01 · FY2022 · CA
Cancer Immunotherapy Clinical Trials
$603,896Christopher Heery · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Mechanisms of Durable Antitumor Immunity Mediated by PI3K-targeted T cells
$603,809Chrystal Mary Paulos · Emory University · R01 · FY2024 · CA
Analysis Of T Cell Receptor Structure And Function
$603,800Ronald Germain · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI
Heterogeneity of T cell phenotype and function in food allergy
$603,747Maria Cecilia Berin · Northwestern University At Chicago · R01 · FY2023 · AI
Heterogeneity of T cell phenotype and function in food allergy
$603,747Maria Cecilia Berin · Northwestern University At Chicago · R01 · FY2024 · AI
Anti-tumor immunity and intestinal microbiota are modulated by mitochondrial DNA
$603,742Douglas C Wallace · Children'S Hosp Of Philadelphia · R01 · FY2024 · CA
Effects of genetic polymorphism in MHC, KIR, and related loci on human disease
$603,715Mary N. Carrington · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Re-wiring PDAC Tumor Immunity Through Dendritic Cells
$603,590David G Denardo · Washington University · R01 · FY2022 · CA
LOCOREGIONAL IRREVERSIBLE ELECTROPORATION FOR MACROPHAGE-MEDIATED IMMUNOTHERAPY OF EARLY-STAGE BLADDER CANCER
$603,534University Of Massachusetts · · FY2020 · Defense Health Agency
Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and Resistance
$603,529Alexander Robertson Allan Anderson · H. Lee Moffitt Cancer Ctr & Res Inst · U01 · FY2020 · CA
Mechanoimmunological interactions between TCR-T cells and tumor fibrotic microenvironment
$603,501Ruogang Zhao · State University Of New York At Buffalo · R01 · FY2025 · CA
A digital intervention to improve skin self-examination among melanoma survivors
$603,475Sharon L Manne · Rutgers Biomedical And Health Sciences · R01 · FY2024 · CA
The roles of EBV-specific T cells in response to checkpoint blockade immunotherapy of EBV-driven nasopharyngeal carcinoma
$603,444Evan Newell · Fred Hutchinson Cancer Center · R01 · FY2023 · CA
The roles of EBV-specific T cells in response to checkpoint blockade immunotherapy of EBV-driven nasopharyngeal carcinoma
$603,444Evan Newell · Fred Hutchinson Cancer Center · R01 · FY2022 · CA
Combinatorial Immunotherapy using a Multivalent Drug Conjugate for GBM Treatment
$603,422Waldemar Debinski · Wake Forest University Health Sciences · R01 · FY2025 · CA
Engineering of pan-neutralizing anti-HIV envelope antibodies
$603,410Mohammad Mohseni Sajadi · University Of Maryland Baltimore · R01 · FY2021 · AI
GM-CSF, macrophages, and susceptibility to Mycobacterium abscessus pulmonary infection
$603,343Katherine B Hisert · National Jewish Health · R01 · FY2024 · HL
Low dose IL-2 and human regulatory T cells
$603,337Thomas R Malek · University Of Miami School Of Medicine · R01 · FY2021 · AI
Low dose IL-2 and human regulatory T cells
$603,337Thomas R Malek · University Of Miami School Of Medicine · R01 · FY2019 · AI
Low dose IL-2 and human regulatory T cells
$603,337Thomas R Malek · University Of Miami School Of Medicine · R01 · FY2022 · AI
Low dose IL-2 and human regulatory T cells
$603,337Thomas R Malek · University Of Miami School Of Medicine · R01 · FY2020 · AI